Dr. Carl Laskin is an internationally recognized expert in the specialized field of Reproductive Immunology and Autoimmune Diseases in Pregnancy. He is well known for his clinical and research activities in the field of fertility medicine and recurrent pregnancy loss, as well as pregnancy in women with autoimmune diseases such as systemic lupus erythematosus. In 1985, he established the Treatment and Evaluation of Recurrent Miscarriage (TERM) Programme, that quickly became Canada’s largest program devoted to the study and treatment of ‘unexplained’ recurrent miscarriage. Today, along with Dr. Sony Sierra, Dr. Laskin runs the expanded Recurrent Pregnancy Loss program at TRIO. This program continues to be the largest program in Canada focused on the investigation and management of recurrent pregnancy loss. Dr. Laskin is also Managing and Founding Partner of TRIO Fertility.
Dr. Carl Laskin obtained his MD from McMaster University in 1975 and completed his training in internal medicine and rheumatology in 1980 at the University of Toronto. From 1980-83, he was a Visiting Fellow in Immunology at the National Institutes of Health in Bethesda, Maryland. Since 1983, he has been an Associate Professor at the University of Toronto in the Division of Rheumatology in the Department of Medicine, with a cross-appointment to the Department of Obstetrics and Gynecology (REI). He is a Founding Partner of LifeQuest Centre for Reproductive Medicine, and TRIO Fertility, as well as the founding Director of the Obstetric Medicine Program, Department of Medicine, University of Toronto.
Dr. Laskin has been invited to present the results of his research on the role of the immune system in recurrent pregnancy loss at numerous international medical conferences in North America and Europe. His research has been published in the New England Journal of Medicine, as well as many other peer-reviewed publications.
Dr. Laskin is a Past President of the Canadian Fertility and Andrology Society (CFAS). He remains actively involved in this organization, and is currently on the Government Relations Committee.